Copaxone and Injection site erythema - a phase IV clinical study of FDA data

Summary:

Injection site erythema is found among people who take Copaxone, especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Copaxone and have Injection site erythema. It is created by eHealthMe based on reports of 53,633 people who have side effects when taking Copaxone from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 08, 2023

53,633 people reported to have side effects when taking Copaxone.
Among them, 1,708 people (3.18%) have Injection site erythema.

What is Copaxone?

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. eHealthMe is studying from 54,216 Copaxone users for its effectiveness, alternative drugs and more.

What is Injection site erythema?

Injection site erythema (redness at injection site) is found to be associated with 2,131 drugs and 1,364 conditions by eHealthMe.

Number of Copaxone and Injection site erythema reports submitted per year:

Could Copaxone cause Injection site erythema?

* Approximation only. Some reports may have incomplete information.

Do you take Copaxone and have Injection site erythema?

Check whether Injection site erythema is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .

Related studies

How severe was Injection site erythema and when was it recovered:

Injection site erythema in Copaxone

Expand to all the drugs that have ingredients of glatiramer acetate:

Injection site erythema and drugs with ingredients of glatiramer acetate

Alternative drugs to, pros and cons of Copaxone:

Copaxone (54,216 reports)

Common Copaxone side effects:

Browse all side effects of Copaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Injection site erythema treatments and more:

Injection site erythema (105,844 reports)

COVID vaccines that are related to Injection site erythema:

Common drugs associated with Injection site erythema:

All the drugs that are associated with Injection site erythema:

Injection site erythema (2,131 drugs)

Common conditions associated with Injection site erythema:

Rheumatoid arthritis: 31,162 reports
Psoriasis: 9,364 reports
Multiple sclerosis: 7,551 reports
Osteoporosis: 4,868 reports
Crohn's disease: 4,176 reports

All the conditions that are associated with Injection site erythema:

Injection site erythema (1,364 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on glatiramer acetate (the active ingredients of Copaxone) and Copaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.